Clinical-stage opportunity PanTher is a clinical-stage oncology company with a proprietary localized delivery platform Sagittari, presenting a potential partner or client for pharma to co-develop or license localized treatment approaches for solid tumors.

Lead candidate focus Lead candidate PTM-101 targets localized non-metastatic pancreatic cancer and potentially other solid tumors, suggesting sales focus areas in oncology therapeutic delivery solutions and expansion opportunities into additional indications.

Expansion footprint Recent Texas expansion and relocation indicate growth potential and heightened regional engagement; this presents opportunities for local supplier partnerships, CRO/CMO services, and regional sales targeting.

Governance signals Board expansions and executive chair appointment signal maturity and increased strategic activity, aligning with potential collaboration in licensing, strategic investments, or joint development deals.

Funding momentum Historically secured multiple rounds and grants totaling over 21 million, plus early-stage revenue range, suggesting readiness for deal structuring, grant-assisted partnerships, and partner-led financing for platform adoption.